HLB (028300) Q4 2025 earnings summary

Executive summary

• Completed merger with HLB Science to streamline R&D, reduce overlapping costs, and enhance competitiveness in drug development, with expected synergies in clinical, regulatory, and commercialization capabilities.

• Maintained diversified operations across biopharma, healthcare devices, and shipbuilding, with continued investment in global clinical trials and expansion of product pipelines.

• Issued multiple convertible bonds and warrants to secure funding for R&D, operations, and strategic investments, while managing liquidity and capital structure.

Financial highlights

• FY2025 consolidated revenue: KRW 84,173 million, up 23.6% year-over-year, driven by new subsidiary sales and expanded shipbuilding business.

• Operating loss narrowed to KRW 104,217 million from KRW 118,516 million in FY2024, reflecting improved cost efficiency despite ongoing R&D investment.

• Net loss attributable to owners: KRW 228,030 million, up from KRW 91,980 million in FY2024, mainly due to increased R&D and impairment charges.

• Total assets: KRW 930,178 million (+4.8% YoY); total liabilities: KRW 435,764 million (+85.2% YoY); equity: KRW 494,414 million (-24.2% YoY).

• Cash and cash equivalents at year-end: KRW 40,983 million, down from KRW 93,048 million.

Outlook and guidance

• Focus on accelerating commercialization of lead oncology assets, especially Rivoceranib (liver cancer) and Lirafugratinib (bile duct cancer), with ongoing regulatory submissions in the US and EU.

• Continued investment in R&D and pipeline expansion, with strategic use of capital from recent bond issuances.

• Targeting operational synergies and cost savings from the HLB Science merger, with expected improvement in profitability and cash flow.